STING-IN-19
STING-IN-19 is a STING inhibitor with a Kd value of 2.31 μM for human STING. STING-IN-19 inhibits the activation of TBK1 and IRF3 by binding to STING, thereby suppressing the activation of downstream signaling pathways. STING-IN-19 reduces the levels of key inflammatory cytokines IL-1β, IL-6 and TNF-α in colonic tissues and serum of mice with ulcerative colitis. STING-IN-19 can be used in studies related to ulcerative colitis.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- 화학식: C30H41NO5
- 분자량:495.65
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
IC50 & Target
[1]|
TBK1 |
IL-1β |
IL-6 |
TNF-α |
In Vitro
STING-IN-19 (compound Z55) binds directly to recombinant human STING1 with high affinity, with a Kd value of 2.31 μM; it potently inhibits HT-DNA-induced STING pathway activation in IRF-Luc-THP-1 cells, with an IC50 of 0.40 μM; it exhibits moderate cytotoxicity against IRF-Luc-THP-1 cells, with a cell viability IC50 of 4.75 μM[1].
STING-IN-19 (10 μM; 18 h) directly binds to endogenous STING in RAW264.7 cells, increasing the thermal stability of this protein by 4.31 °C[1].
STING-IN-19 potently inhibits DMXAA-induced activation of the STING pathway in RAW264.7 murine macrophages, and exhibits no cytotoxicity at concentrations up to 3 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW264.7 cell
-
Concentration:10 μM
-
Incubation Time:18 h
-
Result:Directly engaged endogenous STING in RAW264.7 cells, increasing the protein's thermal stability by 4.31 °C.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, 8 weeks old, 20-22 g, DSS-induced ulcerative colitis)[1]
-
Dosage:2, 4 mg/kg
-
Administration:i.p.; daily; 7 days
-
Result:Significantly attenuated DSS-induced body weight loss.
Reduced Disease Activity Index (DAI) scores.
Alleviated colon shortening, with 4 mg/kg dose showing greater efficacy than 2 mg/kg.
Protected against crypt architecture destruction, reduced inflammatory cell infiltration, and preserved goblet cells (assessed via H&E and PAS staining).
Significantly downregulated protein expression levels of p-STING, p-TBK1, and p-IRF3 in colon tissues at 4 mg/kg.
Reduced serum levels of inflammatory cytokines IL-1β, IL-6, and TNF-α.
Downregulated mRNA expression of IL-1β, IL-6, and TNF-α in colonic tissues.
Chemical Information
-
분자량 495.65
-
화학식 C30H41NO5
-
SMILES
O=C(O[C@@H]1C[C@](CC[C@]2([H])[C@]3([H])CC[C@@]4(C)[C@]2(O5)[C@H]5C[C@@H]4C6=COC(C=C6)=O)([H])[C@]3(C)CC1)[C@H]7NCCCC7
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)